文献速递临床试验与 GCP基础与转化研究

茵芪三黄抗病毒汤治疗慢性乙型肝炎的随机安慰剂对照双盲试验方案

Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial.
PubMed 文献 · Trials · 2020-06-05

这是一项多中心、随机、安慰剂对照、双盲试验方案,纳入802例慢性乙型肝炎患者,随机分为茵芪三黄抗病毒汤联合恩替卡韦组与安慰剂联合恩替卡韦组,各401例。主要结局为肝硬化年发生率,治疗52周后随访52±2周,旨在评估联合治疗的有效性与安全性。

要点

  • 茵芪三黄抗病毒汤联合恩替卡韦对比安慰剂联合恩替卡韦,主要结局为肝硬化年发生率。
  • 样本量802例,两组各401例,治疗52周、随访52±2周。
  • 次要结局包括HBV DNA阴性率、HBsAg阴性率、HBeAg血清学转换率及肝功能等。

核心结论

  • 该试验旨在评估茵芪三黄抗病毒汤联合恩替卡韦减少肝纤维化/肝硬化年发生率至1%的效果与安全性。

研究设计与样本

  • 多中心、随机、安慰剂对照、双盲试验,涉及五家医院。
  • 共802例患者随机分为YQSH组(n=401)与安慰剂组(n=401)。

关键数值与推荐

  • YQSH组接受茵芪三黄抗病毒汤联合恩替卡韦,安慰剂组接受安慰剂颗粒联合恩替卡韦。
  • 治疗52周,随后随访52±2周。
  • 主要结局指标为肝硬化年发生率。
  • 次要结局包括HBV DNA阴性率、HBsAg阴性率、HBeAg血清学转换率、肝功能指标、脾厚度、临床症状评分及安全性评估。

临床怎么用

  • 该方案拟为中药联合常规抗病毒药物治疗慢性乙型肝炎提供临床证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic hepatitis B (CHB) is a global public health problem. Antiviral therapy is the primary treatment. Studies have shown that a combined therapy of traditional Chinese medicine (TCM) and conventional antiviral drugs has better efficacy than conventional antiviral for treatment of CHB. YinQiSanHuang-antiviral decoction (YQSH) is a TCM compound preparation that has shown an effect on anti-hepatitis B virus and on slowing progression of hepatitis B-related liver diseases. To evaluate the efficacy and safety of YQSH combined with entecavir and its preventive effect on hepatitis B cirrhosis, we designed this randomized, double-blind and placebo-controlled trial. The objective is that the combination of YinQiSanHuang-antiviral decoction with entecavir will reduce the annual incidence of liver fibrosis/cirrhosis to 1%. METHODS: This is a multicenter, randomized, placebo-controlled, double-blinded trial involving five hospitals. A total of 802 patients are randomly allocated to two groups: the YQSH group (n = 401) or the placebo group (n = 401). The YQSH group receives YQSH with entecavir; the placebo group receives granules of placebo with entecavir. Patients receive treatment for 52 weeks and then are followed up for 52 ± 2 weeks. The primary outcome measure is the annual incidence of cirrhosis. The secondary outcome measures are hepatitis B virus DNA negative rate, hepatitis B surface antigen negative rate, hepatitis B e antigen seroconversion rate, liver function (alanine aminotransferase, aspartate aminotransferase , gamma-glutamyl transferase , alkaline phosphatase , serum albumin, and total bilirubin), spleen thickness, evaluation scores of patients' clinical symptoms, and safety assessment. Outcomes will be assessed at baseline and after treatment. DISCUSSION: Combination therapy could become a trend for treatment of CHB, and this trial expects to provide credible clinical evidence for the future combination of TCM and conventional antiviral drugs for the treatment of CHB. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR1900021521. Registered on 25 February 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wu QJ, Lv WL, Li JM, et al. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial. Trials. 2020. PMID: 32503608. doi:10.1186/s13063-020-04395-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。